“Digital transformation” is a common buzzword across industries today, but is it more than just jargon? Faced by shifting consumer demand, rapidly evolving technology and increasing competition, organizations — to a large extent from science-based industries — are realizing that business as usual (or only incremental change to traditional approaches) does not address today’s challenges in a sustainable, long-term way.
If current manufacturing practices are followed to handle small batches of API on industrial size machines, it results in handling difficulties and lower product yield.
A solution to bridge the gap between laboratory and manufacturing scale lyophilizers.
Formulation techniques and technologies can easily become more habit than science, but a single technology does not work for all compounds. Each new drug is unique and deserves a fresh approach to formulation.
One tool holds a unique position among R&D informatics systems -- electronic laboratory notebooks (ELNs). ELNs both produce data and consume information and are particularly powerful.
How an agnostic and data-driven approach early on can optimize the development pathway to bring the molecule to the market faster.
Help sponsors design a more holistic strategy to their managing the clinical supply returns process.
Growing evidence demonstrates that the number of noninfectious viral particles in a sample is of significant biological importance and can impact both in vitro and in vivo studies.
Biocom, the association representing the life science industry of California, concluded its Regenerative Medicine Advocacy Fly-In to Washington, D.C. yesterday, the culmination of almost a year of efforts to elevate the voice of California’s regenerative medicine community